ZVSA ZyVersa Therapeutics
- 5.3000
- -0.1600-2.93%
ZyVersa Therapeutics News
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
What's Going On With ZyVersa Stock?
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for
ZyVersa Therapeutics Stock Jumps 8%
ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt
ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt
ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings Among Healthcare Movers
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC With IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients With Alzheimer's Disease
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates that multiple inflammasome triggers (NLRP1 and pyrin)
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
PEGY, CGEM and IFBD Among Mid-day Movers
ZyVersa Therapeutics To Carry Out 1-for-10 Reverse Stock Split On April 26th, 2024
April 25th - $ZyVersa Therapeutics(ZVSA.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 26th, 2024.$ZyVersa Ther
ZyVersa Therapeutics Approves Reverse Stock Split
ZyVersa Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
ZyVersa Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Buy Rating Affirmed: ZyVersa Therapeutics' Promising Pipeline and Strategic Advancements
HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates ZyVersa Therapeutics with a Buy and maintains $12 price target.
Zyversa Therapeutics' 1-for-35 Reverse Split: Navigating the Risks to Shareholder Value and Liquidity
ZyVersa Therapeutics GAAP EPS of -$0.29
ZyVersa Therapeutics FY23 EPS $(108.97)
ZyVersa Therapeutics FY23 EPS $(108.97)
Press Release: ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Key Highlights: -- Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical tria
ZyVersa Gets IRB Nod for Kidney Drug Phase 2a Trial
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA), a biopharmaceutical company, has received Institutional Review Board (IRB) approval to proceed with a Phase 2a clinical trial for its Cholesterol Efflux Mediator VAR 200, a drug under development for the treatment of diabetic kidney disease.
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients With Diabetic Kidney Disease
Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic
Analysis
Price Target
No Data
